

Report 37: Children's role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility

Katy A.M. Gaythorpe^{1*}, Sangeeta Bhatia^{1*}, Tara Mangal^{1*}, H. Juliette T. Unwin^{1*}, Natsuko Imai^{1*}, Gina Cuomo-Dannenburg^{1^}, Caroline E. Walters^{1^}, Elita Jauneikaite^{1^}, Helena Bayley², Mara D. Kont¹, Andria Mousa¹, Lilith Whittles¹, Steven Riley¹, Neil M. Ferguson¹

¹ MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for Infectious Disease Modelling, Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London

² Department of Physics, University of Oxford

Correspondence: k.gaythorpe@imperial.ac.uk,

*contributed equally; ^contributed equally,

SUGGESTED CITATION

KAM Gaythorpe, S Bhatia, T Mangal *et al.* Children's role in the COVID-19 pandemic: as systematic review of early surveillance data on susceptibility, severity, and transmissibility. Imperial College London (19-11-2020), doi: <https://doi.org/10.25561/->.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Summary

SARS-CoV-2 infections have been reported in all age groups including infants, children, and adolescents. However, the role of children in the COVID-19 pandemic is still uncertain. This systematic review of early studies synthesises evidence on the susceptibility of children to SARS-CoV-2 infection, the severity and clinical outcomes in children with SARS-CoV-2 infection, and the transmissibility of SARS-CoV-2 by children.

A systematic literature review was conducted in PubMed. Reviewers extracted data from relevant, peer-reviewed studies published during the first wave of the SARS-CoV-2 outbreak using a standardised form and assessed quality using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. For studies included in the meta-analysis, we used a random effects model to calculate pooled estimates of the proportion of children considered asymptomatic or in a severe or critical state.

We identified 2,775 potential studies of which 128 studies met our inclusion criteria; data were extracted from 99, which were then quality assessed. Finally, 29 studies were considered for the meta-analysis that included information of symptoms and/or severity, these were further assessed based on patient recruitment. Our pooled estimate of the proportion of test positive children who were asymptomatic was 21.1% (95% CI: 14.0 - 28.1%), based on 13 included studies, and the proportion of children with severe or critical symptoms was 3.8% (95% CI: 1.5 - 6.0%), based on 14 included studies. We did not identify any studies designed to assess transmissibility in children and found that susceptibility to infection in children was highly variable across studies.

Children's susceptibility to infection and onward transmissibility relative to adults is still unclear and varied widely between studies. However, it is evident that most children experience clinically mild disease or remain asymptomatically infected. More comprehensive contact-tracing studies combined with serosurveys are needed to quantify children's transmissibility relative to adults. With children back in schools, testing regimes and study protocols that will allow us to better understand the role of children in this pandemic are critical.

1. Introduction

Cases of atypical pneumonia were first reported in Wuhan City, China in late 2019. Since then, SARS-CoV-2 has spread rapidly across the globe and the World Health Organization declared COVID-19 a pandemic on March 11, 2020 [1]. As of November 17, 2020 there have been a total 55,154,651 reported cases and 1,328,537 deaths [2]. In the absence of effective therapeutics or vaccines early in the pandemic, countries implemented a range of non-pharmaceutical interventions (NPIs) to limit the spread of the virus.

Based on what was known about the role of children in the spread of influenza during pandemics, school closures were widely implemented with an estimated 80-100% of EU/EEA countries across the world closing pre-schools, primary schools, secondary school, and higher education institutions as the pandemic progressed from February 2020 in East Asia to late April across Europe and the Americas [3–5]. Widespread NPIs and effective “lockdowns”, many including school-closures, have had a substantial role in suppressing transmission [6]. However, changes in contact patterns due to these measures have made it difficult to understand the extent to which children are infected by SARS-CoV-2 or are able to transmit SARS-CoV-2 onto others. Children and young adults represent a small proportion of the total reported cases of COVID-19 globally thus far, but the fraction of severe cases and deaths amongst this age group is small [7]. There is now a large body of evidence [7–12] for the age-dependency in clinical cases with severe cases and deaths concentrated in the elderly and amongst those with comorbidities. However, while there is consensus that children generally have milder clinical symptoms [7, 13, 14], it is important to note that early routine testing and diagnosis were restricted mainly to symptomatic cases requiring health care in most countries. Therefore, data reported by countries through routine surveillance systems are likely to significantly under-estimate cases amongst those with mild or no symptoms.

In addition, the widespread social distancing (SD) measures, such as restrictions on gatherings, encouragement to work from home, and closures of bars and restaurants, have substantially impacted contact patterns between individuals [15] and universal school-closures will have significantly affected how much children interact with others. Thus far, outbreaks of COVID-19 in schools have not been widely reported. However, national holidays and school closures in response to the pandemic would have changed the risk of exposure to SARS-CoV-2 infection by reducing the number of non-household contacts that children have. It has been suggested that children are less susceptible to SARS-CoV-2 infection due to differences in their innate immune system, which means a faster and broader immune response can be mounted [16]. However, a flat attack rate has been observed across different age groups in contact-tracing studies [17], population-based infection surveys [18] and retrospective seroprevalence surveys [19, 20]. This is typical of a novel pathogen in a population with no prior immunity. There is also increasing evidence that the age-distribution of newly detected cases is shifting towards younger age groups which may be captured as a result of the expanded test capacity in many countries including the UK and USA compared to April 2020 [21]. This shift is now starting to be reflected in increased hospitalisations amongst young adults (20 – 35 years old), but whether children will also be affected at the same rate is yet to be seen [22].

The biggest uncertainty is whether children are intrinsically less infectious than adults and whether they can contribute to onward transmission. Within household clusters, children are not often identified as the index case, but this is difficult to determine due to the age-dependent clinical symptoms and a larger proportion of infections in children appearing to be asymptomatic [23]. The correlation between clinical

severity and transmissibility is also difficult to disentangle, since pre-symptomatic transmission has been shown to be an important driver of transmission within the population [24–26]. It is unclear to what extent mild and asymptomatic cases also contribute to onward transmission at any age [27].

Policies around schools are being adjusted based on new evidence and the level of transmission in each country. With growing concern about the long-term developmental and mental health impacts of school closures on children, the safe re-opening of schools has become a priority across different governments. Understanding the role of children in SARS-CoV-2 transmission is therefore critical in guiding ongoing policy for schools conducting face-to-face education.

In this study we undertook a systematic review of the peer-reviewed literature, excluding pre-prints, to synthesize available data on three specific topics: i) the susceptibility of children to SARS-CoV-2 infection; ii) the severity and clinical outcomes in children with SARS-CoV-2 infection; and iii) the transmissibility of SARS-CoV-2 by children. We conducted a meta-analysis of data collected to address these topics and discuss their implications for future public health policies. The studies included reflect the early evidence generated during an emerging outbreak, where large population serosurveys and extensive contact tracing were uncommon.

2. Methods

2.1 Literature search

Our methods adhere to the guidelines established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Our study protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews) under the identifier #CRD42020184605.

We searched PubMed for "(*sars-cov-2* OR *nCov* OR *covid-19*) AND *children* AND (*infection* or *susceptibility* or *transmission* or *shedding* or *symptomatic*)". As SARS-CoV-2 is a new human pathogen, we restricted our searches to records from 2019 and 2020. The initial search was conducted on May 6, 2020 and repeated on July 4, 2020. All records were imported into Covidence (v2014, accessed 2020) and de-duplicated. Both the titles/abstract and full-text screening were conducted by at least two independent reviewers and any conflicts resolved by consensus. Cohort studies, contact-tracing studies and population surveys were included. We excluded: i) non-peer reviewed studies; ii) case reports reporting fewer than 10 cases due to the high potential for bias and limited amount of information; iii) papers focusing on vertical transmission; and iv) non-English language papers. Full inclusion and exclusion criteria can be found in the Supplementary Information.

Outcomes of interest were the risk in children of infection with COVID-19 following exposure i.e. aged distributed attack rate (up to 18 years of age); the risk of onward transmission of COVID-19 to contacts of an infected child i.e. secondary attack rates from a paediatric index case; and the proportion of symptomatic children and their disease severity (defined as mild disease/asymptomatic or severe disease requiring hospital care) of all children with confirmed COVID-19 infection.

2.2 Data extraction and quality assessment

Data extraction was performed by all investigators using an Excel spreadsheet. Data collected included the type of study (e.g. cohort), country of origin, number of patients or size of cohort considered, demographic information (including age and sex where available), clinical symptoms and severity, and seroprevalence or attack rates where available (Supplementary Information Table S1).

The methodological quality of included studies was assessed by two reviewers using 10-item questions, which we adapted from the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [28] to assess the strength of evidence relating to our research questions specifically e.g. assessing if the case definitions were clearly specified in the study (Supplementary Information Tables S2 & S3). Studies that scored 7 or more points were classified as good, those that scored 5 or 6 points were rated as fair, and any study that scored fewer than 5 points was rated as poor at informing our research questions.

2.3 Data analysis

All extracted studies were filtered by topic, so data analysis was conducted only on studies including details on the quantity of interest, for example the number of individuals classed as asymptomatic. For the purposes of our analysis, we defined children as individuals aged 18 years or younger. The filtered studies were then checked for comparability, based on study type. Random effects modelling was performed using R package *metaphor* [29] to produce estimates of the proportion of children considered asymptomatic or in a severe/critical state. We used an empirical Bayes estimator for the level of heterogeneity and weighted by the size of the study population. Analyses were conducted using R package *orderly* version 1.1.29 [30] in R version 3.6.3.

3. Results

3.1 Literature search

A total 2,775 potential studies were found, and 148 duplicates removed. Title and abstracts for 2,627 studies were screened. 633 studies fulfilled the inclusion criteria and were assessed for full-text evaluation. 505 full texts that did not meet the final inclusion criteria were excluded generating a final list of 128 studies included for analysis. The final number of studies included in the meta-analysis was 29 (Figure 1).




Figure 1: PRISMA flow chart detailing the literature search process.




Figure 2: Distribution of studies over geography and time. A) The distribution of studies globally where the label denotes number of studies in a country and colour denotes earliest recorded study start date. B) Study locations in China where dot size corresponds to number of participants in entire study. C) The distribution of studies in a subset of European countries where the label denotes number of studies in a country and colour denotes earliest recorded study start date. Studies including individuals from multiple countries, or without a city in China, were omitted from the map, n=10.

The study locations and study dates followed the pandemic trajectory with the majority of early studies conducted in China (45 studies [11, 17, 25, 26, 27, 28–32, 33–42, 43–52, 53–62, 63–65]) and later studies conducted in Europe (26 studies [10, 72–96]) and North America (12 studies [97–108]) (Figure 2). There were no studies that matched the inclusion criteria from South America or Africa. We include the study timings to show potential spatial and temporal bias in our data.

3.2 Severity

3.2.1 Proportion asymptomatic

29 studies with information on the size of the population considered COVID-19 positive by PCR and the number of individuals considered asymptomatic in those aged 18 or less were included [10, 33, 41, 42, 45–47, 49, 50, 54, 55, 58, 62, 64–66, 69, 78, 79, 81, 85, 86, 89, 92, 102, 109–112]. The majority of studies were cohort studies or case series; follow-up was sometimes not detailed. One study (Hu et al. [113]) was omitted during data extraction because the study population only selected asymptomatic children. The other studies were assessed for inclusion in the meta-analysis based on their recruitment of study participants and whether this was clear and unbiased. All studies are detailed in Table S4 in the supplementary material as well as a meta-analysis containing all studies. 14 studies fulfilled this additional criterion and the proportion of individuals considered asymptomatic in each included study is shown in Figure 3. Our pooled estimate of asymptomatic children was 21.1% (95% CI: 14.0 - 28.1%) with a τ^2 (between-trial-variance) of 0.014 (95%CI:0.004 - 0.057). This indicates low variability between studies with information on the size of the population considered COVID-19 positive by RT-PCR and the number of individuals considered asymptomatic in those aged 18 or less that were included in our analysis. These estimates are consistent with estimates of asymptomatic infections in the wider population (20% 95CI[17-25]) although this was found to vary between settings [24]




Figure 3: Proportion of SARS-CoV-2 positive children who are defined as asymptomatic at the time of the study in each published study. The random effects model result is given at the bottom indicated by a blue diamond. The squares are proportional in size to the number of COVID-19 positive individuals in the study. All studies were conducted in 2020. The labels on the left provide first author, the labels on the right give point estimate and confidence interval of the asymptomatic proportion estimated. Studies are ordered by the mean of the age range with age range given in blue on the right. Studies were included where recruitment criteria were clear and unbiased.

13 studies with information on the size of the population considered COVID-19 positive by PCR and the number of individuals considered severe or critical in those aged 18 or younger were included [10, 41, 46, 49, 50, 54, 64–66, 69, 78, 86, 102]. Most studies were hospital-based and were based on PCR-confirmed cases only. Whilst the majority were symptomatic children brought for clinical care only a small number of studies included asymptomatic PCR positive children at time of test. We again omitted Hu *et al.* [113] as this study population focused on asymptomatic children only. We estimated that overall, 3.76% (95% CI: 1.52 - 6.01%) of children had severe or critical symptoms pooled across studies (Figure 4). The estimated τ^2 (between-trial-variance) was 0.0013 (95%CI: 0.0003 - 0.0049), which again indicates low variability between studies.




Figure 4: Proportion of COVID-19 positive children who were defined as severe or critical in each available study. The random effects model result is given at the bottom indicated by a blue diamond. The squares are proportional in size to the number of COVID-19 positive individuals in the study. All studies were conducted in 2020. The labels on the left provide first author, the labels on the right give point estimate and confidence interval of the proportion. Studies are ordered by the mean of the age range with age range given in blue on the right.

3.3 Transmissibility

We did not identify any studies that were designed specifically to measure SARS-CoV-2 transmissibility in children. As such there is limited quantitative evidence to understand whether children are less likely to transmit SARS-CoV-2 to others compared to adults.

We identified one case series [52] that confirmed SARS-CoV-2 transmission from an infant to both parents. Amongst paediatric cases identified in Ireland who attended school during their pre-symptomatic and symptomatic periods of infection (n=3), no instances of onward transmission to either children or adults were identified [114]. Danis *et al.* [96] detailed contact tracing of a cluster of cases in a French ski chalet. One paediatric case had a large number of contacts within a school setting (112 contacts) whilst

symptomatic. However, contact tracing efforts did not identify any instances of onward transmission. Zachariah *et al.* [104] reported two parents in New York, USA, developing symptoms consistent with COVID-19 whilst visiting their hospitalised child, although we note the parents could have been infected outside the hospital or by other hospitalised individuals. A large-scale contact tracing study in South Korea estimated that rates of infection were higher for contacts in households where the index patient was 10 – 19 years old (18.6%, 95% CI: 14.0 – 24.0%) compared to 11.8% (95% CI: 11.2 – 12.4%) of all household contacts of COVID-19 index cases [115].

3.4 Susceptibility to infection

We identified only five studies [17, 18, 61, 77, 109] that reported age-specific attack rates (AR) from contact tracing studies based on symptomatic surveillance for the index case and retrospective or prospective cohort studies, and these varied substantially between studies.

Based on contact-tracing studies in China, Bi *et al.* [17], reported similar attack rates across all age groups in Shenzhen with a 7.4% attack rate in young children (<10 years) compared to the population average of 6.6%. Liu *et al.* [61] estimated a higher attack rate in Guangdong Province amongst children aged <10 years and 10-19 years (5.7% and 4.0% respectively) compared to 20-29 year olds with the lowest AR of 2.3%. Conversely, PCR screening of 745 “highly suspected” children and 3,174 adults found that adults were significantly more likely to test positive (1.3% in children vs 3.5% in adults) [109]. Those screened were individuals who had contact with a confirmed SARS-CoV-2 patient in the past 14 days or were identified as part of a familial outbreak in Guangzhou between 22 January and 20 February 2020.

From studies in Europe, Lavezzo *et al.* [77], did not detect a single SARS-CoV-2 positive amongst children aged <10 years across two population wide surveys in Vo, Italy. They also found attack rates amongst older children aged 11 – 20 years were comparable to those observed in adult age groups. Similarly, population-based screening for SARS-CoV-2 in Iceland did not identify any SARS-CoV-2 positive children aged <10 years. In individuals deemed at high risk due to recent overseas travel or COVID-like symptoms and targeted for testing, 6.7% of children aged <10 years tested positive compared to 13.7% of those aged 10 years and above [18].

We identified one study reporting age-specific seroprevalence from Geneva, Switzerland. Stringhini *et al.* found that young children aged 5-9 years had a significantly lower risk of being seropositive (RR 0.32, 95% CI 0.11 – 0.63) compared to adults 20-49 years [72]. This variability in age-specific infection rates between studies was also reflected amongst the studies that reported SARS-CoV-2 infection prevalence in children and adults (Figure 5) [17, 31, 39, 44, 59, 61, 73, 75, 77, 79, 96, 100, 103, 110, 116, 117].

Although the source of infection amongst children could not be assessed systematically, studies identified through the review suggest that transmission to children tended to occur within household settings from other family members in family clusters although for the majority schools were closed during the first wave [10, 45]. Many children had a history of close contact with at least one parent who was SARS-CoV-2 positive [35, 48, 80]. Chen *et al.* [48] observed, based on small numbers, that this family aggregation was consistent amongst infants and pre-school children (7 of 8), and school-aged children (14 of 16) but not in adolescents (1 of 8).




Figure 5: The age-specific prevalence shown as the proportion of confirmed SARS-CoV-2 cases by the mean age of the group. Studies were included if the maximum age was >18 (i.e. they included both children and adults) and estimated the prevalence of infection in the cohort.

4. Discussion

We identified 128 studies that provided information on the early impact of the COVID-19 pandemic on children and their potential role in transmission that met our eligibility criteria. Most studies were from China, Europe, and North America and there were no eligible studies from low- and middle-income countries notably from South America or Africa.

Adding to the growing body of evidence that SARS-CoV-2 infection in children are less severe than in adult populations, we estimated from 14 early studies that 21.1% (95% CI: 14.0 - 28.1%) of SARS-CoV-2 infections in children were asymptomatic. These studies were mainly paediatric cohort studies that swabbed children based on their recent exposure history with a confirmed COVID-19 patient. A small number of studies were retrospective or a case series, detailed in the supplementary material. Furthermore, our pooled estimate across 13 studies of the proportion of children with confirmed severe or critical COVID-19 symptoms was low at 3.8% (95% CI: 1.5 - 6.0%). Most of the 13 studies were based on symptomatic children brought to hospital for clinical care and only a small number of studies included asymptomatic PCR positive children at time of test. These estimates are consistent with recent findings from South Korea where 22.0% of SARS-CoV-2 positive children remained asymptomatic for the duration of infection and only 3% of cases were severe [118]. Although slightly older, a recent study in a young military cohort in the USA (median age: 25

years, interquartile range: 22 – 31 years) also reported that 19.8% (146/572 individuals) remained asymptomatic for the duration of the study [119]. However, modelled estimates of the clinical fraction by age using data from 6 countries estimated that almost 80% of infections in children aged 10-19 years were asymptomatic (only 21% (95% CrI: 12 – 31%) of infections in 10-19 year olds leading to clinical symptoms) [11]. The estimated proportion of asymptomatic infections in the population across all ages varies widely between studies. He *et al*, based on 41 studies of confirmed COVID-19 estimated a pooled percentage 15.6% (95% CI, 10.1%-23.0%) infections being asymptomatic with significant heterogeneity noted among studies [120]. Another meta-analysis by Zhang *et al*. [121] based on early data from the pandemic across all ages estimated pooled rates of intensive care unit admission, acute respiratory distress syndrome, and death of 10.9%, 18.4%, and 4.3% respectively.

However, there is now increasing evidence that critically ill children can develop a multi-inflammatory syndrome temporally associated with SARS-CoV-2 infection known as Multisystem Inflammatory Syndrome in Children (MIS-C) that significantly increases the risk of children with COVID-19 requiring intensive case [7, 122–124].

It is important to note that this systematic review is based on studies conducted early in the pandemic, predominantly within China. Recent large-scale population-based studies run by the Office for National Statistics [125] and the REACT-1 [126] study in the UK have suggested that the proportion of asymptomatic infections may be as high as 67% across all age groups in the UK. However, this figure also included individuals who did not respond to questions related to symptoms and pre-symptomatic individuals for the ONS and REACT-1 studies, respectively.

As of August 6th, children still represented less than 5% of overall COVID-19 cases reported to the European Centre for Disease Prevention and Control and deaths among cases under 18 years were extremely uncommon [3]. This is indicative that SARS-CoV-2 infections amongst children may be less symptomatic or severe than adults as testing policies across Europe thus far have prioritised symptomatic or hospitalised cases. Only a minority of children have required hospital care in the UK with only 1.5% (310 out of 20,133) of patients in the UK aged <18 years [9]. These patterns were also observed in countries affected early on in the pandemic such as China and Italy with few child-hospitalisations [127]. Although we did not consider fatality estimates in this study, deaths are also highly age-dependent with low case and infection fatality estimates in children [8, 128, 129].

There were limited studies that addressed the transmissibility of children but there was evidence of onward transmission from paediatric index cases [52] and rates of COVID-19 being higher amongst household contacts of children in South Korea [115]. Contrastingly, detailed contact-tracing of secondary contacts of a child in France with a large number of contacts across 3 schools did not identify any secondary cases [96]. There were also no secondary cases reported in a school setting in Ireland [114]. Milder symptoms in children may limit how much virus is expelled, given viral loads in children and adults may be comparable [130, 131], and therefore how infectious children are. However, studies have shown that a substantial amount of transmission occurs before the onset of symptoms [24, 26, 132, 133], suggesting the relationship between transmissibility and symptoms is complex.

Overall, evidence suggests that children are less likely to transmit SARS-CoV-2 compared to adults. A cluster-based study from Japan did not identify any children aged 0 – 19 years as a probable primary case of a cluster [134], a national study in South Korea reported very low secondary household attack rates of 0.5% (95% CI: 0.0 – 2.6%) from paediatric index cases [135], and a prospective study in New South Wales, Australia, similarly identified very few instances of onward transmission from a paediatric index case [136]. A recent detailed study from Tamil Nadu and Andhra Pradesh, India, based on data from 575,071 tested

contacts of 84,965 confirmed cases found that the probability of transmission was assortative by age with the strongest effects observed in children aged 0 – 14 years and adults aged 65 years and above [137].

Most countries implemented full or partial school-closures during the first wave of the pandemic. As schools and other educational institutions re-open across the world, school outbreaks have been increasingly reported, with a large outbreak resulting in a 13.2% attack rate in Israel [138], and 41 out of 825 schools in Berlin reporting an outbreak of COVID-19 within 2 weeks of reopening [139, 140]. However, it is difficult to determine whether transmission occurred primarily in schools or whether pupils were infected at home, or in other social settings. Nevertheless, high attack rates of 44% reported at a youth camp in Georgia, USA suggests that SARS-CoV-2 can transmit readily in young populations [141]. It is likely that school outbreaks will mirror increasing prevalence in the community itself [142]. Whether schools themselves are the drivers of transmission is still unknown, particularly with many containment measures such as cohorts implemented since reopening [143].

Although we were not able to estimate a pooled estimate for age-specific attack rates from the studies identified, they present a mixed picture of comparable, lower, or higher attack rates than adults depending on study setting [17, 61]. Population-based PCR screening in Iceland [18] and Italy [77] and a seroprevalence survey in Geneva, Switzerland [72] suggested that young children (5-9 years) were less susceptible to SARS-CoV-2 infection. This agrees with a recent meta-analysis that included non-peer reviewed studies, which also estimated a lower susceptibility to infection in children and adolescents with a pooled odds ratio of 0.56 (95% CI: 0.37 – 0.85) [144].

There is considerable variation in seroprevalence by age in studies published from multiple countries and settings. Across the USA, 8 out of 10 sites reported the lowest seroprevalence amongst individuals 18 years and younger, although the sample sizes for children were small so it was difficult to accurately estimate seroprevalence in young children [145, 146]. In Tokyo, Japan no children recruited from two community clinics tested seropositive compared to an overall IgG seropositivity of 3.83% (95% CI: 2.76 – 5.16%) [147]. However, other studies have reported no differences in seropositivity between children and adults in Buenos Aires, Argentina [148], Barcelona, Spain [149], and French Guiana [150]. Dingens *et al.* [151] suggest that seroprevalence studies in children only are not able to quantify relative susceptibility compared to adults, but that the frequency of seropositivity is comparable to the overall incidence.

Recent studies showing rapid waning of antibodies, particularly following mild symptoms which are more likely in children, may complicate the picture presented by seroprevalence surveys and their interpretation regarding susceptibility to infection [152, 153].

There are a number of limitations to our study. At the time of review, there were no studies from Africa or South America that met the inclusion criteria. Contact patterns and household structures may differ substantially in these settings from the predominantly high-income countries considered here, which may result in differences that we have not captured. Although we have estimated the pooled proportion asymptomatic based on the values reported by the study authors, we could not assess whether individuals went on to develop symptoms as very few studies reported the length of follow-up, or loss to follow-up. As such, the definition of asymptomatic may vary between included studies, affecting the estimate. Most of the studies considered were undertaken when non-pharmaceutical interventions, including school closures, case isolation, workplace closures and other social distancing measures, were implemented. The substantial change in contact patterns and the increased mixing within households may mean that children have had less opportunities for contact and this decreased chances of becoming infected or transmitting the virus. Therefore, contact tracing studies have likely disproportionately identified transmission within the household [39]. For both population-based infection surveys and seroprevalence studies, the number

of children sampled was small and very few studies differentiated between young children and adolescents who may have different risk profiles. Finally, children may be more likely to be tested depending on healthcare seeking behaviour of parents or because in general they may be more prone to illness causing influenza-like illness symptoms. Both factors may contribute in a higher asymptomatic proportion.

5. Conclusions

As we are entering the second wave of the pandemic in many countries across the world, there is increasing evidence that children are susceptible to SARS-CoV-2 infection, but perhaps to a lesser extent than adults. It is clear, however, that many children experience clinically mild disease or remain asymptotically infected. Although severe disease in children and MIS-C does occur, fatalities due to COVID-19 remain rare. Whilst there is evidence to suggest that children are capable of transmitting SARS-CoV-2, more comprehensive contact-tracing studies combined with serosurveys are needed to quantify their transmissibility relative to adults and determine whether they contribute significantly to the outbreaks. The re-opening of schools will likely highlight and quickly fill key data gaps. It is critical that testing regimes and study protocols are in place that will allow us to better understand the role of children in this pandemic.

6. Acknowledgements

We would like to acknowledge the members of the Imperial College COVID-19 response team.

7. References

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>. Accessed 30 Sep 2020.
2. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of 22 October 2020. <https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases>. Accessed 23 Oct 2020.
3. ECDC. COVID-19 in children and the role of school settings in COVID-19 transmission. 2020. <https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-schools-transmission-August-2020.pdf>. Accessed 28 Sep 2020.
4. United Nations Educational S and CO. School closures caused by Coronavirus (Covid-19). 2020. <https://en.unesco.org/covid19/educationresponse>. Accessed 1 Oct 2020.
5. United Nations Educational S and CO. Global tracking of COVID-19 caused school closures and re-openings. 2020. <https://en.unesco.org/sites/default/files/unesco-map-covid-19-caused-school-closures-and-reopening-methodological-note-en.pdf>. Accessed 1 Oct 2020.
6. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020;584:257–61. doi:10.1038/s41586-020-2405-7.
7. Swann O V, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ*. 2020;370:m3249. doi:10.1136/bmj.m3249.
8. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020.
9. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *Bmj*. 2020;369 PG-m1985:m1985. doi:10.1136/bmj.m1985.
10. Armann JP, Diffloth N, Simon A, Doenhardt M, Hufnagel M, Trotter A, et al. Hospital Admission in Children and Adolescents With COVID-19. *Dtsch Arztebl Int*. 2020;117 21 PG-373–374:373–4. doi:10.3238/arztebl.2020.0373.
11. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med*. 2020.
12. European Centre for Disease Prevention and Control. Epidemiology of COVID-19. <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/epidemiology>. Accessed 13 Nov 2020.
13. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. *EClinicalMedicine*. 2020;24:100433. doi:10.1016/j.eclinm.2020.100433.
14. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspá M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Heal*. 2020; PG-. doi:10.1016/s2352-4642(20)30177-2.
15. Jarvis CI, Van Zandvoort K, Gimma A, Prem K, Klepac P, Rubin GJ, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med*. 2020;18:124.

doi:10.1186/s12916-020-01597-8.

16. Carsetti R, Quintarelli C, Quinti I, Piano Mortari E, Zumla A, Ippolito G, et al. The immune system of children: the key to understanding SARS-CoV-2 susceptibility? *The Lancet Child and Adolescent Health*. 2020;4:414–6. doi:10.1016/S2352-4642(20)30135-8.
17. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis*. 2020; PG-. doi:10.1016/s1473-3099(20)30287-5.
18. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med*. 2020; PG-. doi:10.1056/NEJMoa2006100.
19. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. *The Lancet Infectious Diseases*. 2020;0. doi:10.1016/S1473-3099(20)30631-9.
20. SeroTracker. <https://serotracker.com/Dashboard>. Accessed 30 Sep 2020.
21. Salvatore PP, Sula E, Coyle JP, PhD, Caruso E, PhD, et al. Recent Increase in COVID-19 Cases Reported Among Adults Aged 18–22 Years — United States, May 31–September 5, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69. doi:10.15585/mmwr.mm6939e4.
22. The Guardian. Younger women ‘bearing brunt’ of second wave of Covid in UK | World news | The Guardian. <https://www.theguardian.com/world/2020/sep/22/younger-women-bearing-brunt-of-second-wave-of-covid-in-uk>. Accessed 30 Sep 2020.
23. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis*. 2020; PG-. doi:10.1016/s1473-3099(20)30198-5.
24. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med*. 2020;17:e1003346. doi:10.1371/journal.pmed.1003346.
25. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerg Infect Dis*. 2020;26 5 PG-1052–1054:1052–4. doi:10.3201/eid2605.200198.
26. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020;26:672–5. doi:10.1038/s41591-020-0869-5.
27. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-NCoV infection from an asymptomatic contact in Germany. *New England Journal of Medicine*. 2020;382:970–1. doi:10.1056/NEJMc2001468.
28. National Heart Lung and Blood Institute. Study Quality Assessment Tools. <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>. Accessed 28 Sep 2020.
29. Viechtbauer W. Conducting Meta-Analyses in R with the **metafor** Package. *J Stat Softw*. 2010;36:1–48. doi:10.18637/jss.v036.i03.
30. Rich FitzJohn, Robert Ashton, Alex Hill, Martin Eden, Wes Hinsley, Emma Russell, et al. orderly: Lightweight Reproducible Reporting. 2020. <https://github.com/vimc/orderly>. Accessed 28 Sep 2020.
31. Lu X, Zhang L, Du H, Zhang J, Li YYY, Qu J, et al. SARS-CoV-2 infection in children. *N Engl J Med*. 2020;382 17 PG-1663–1665:1663–5. doi:10.1056/NEJMc2005073.

32. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clin Infect Dis*. 2020; PG-. doi:10.1093/cid/ciaa198.
33. Chen J, Zhang ZZ, Chen YK, Long QX, Tian WG, Deng HJ, et al. The clinical and immunological features of pediatric COVID-19 patients in China. *Genes Dis*. 2020; PG-. doi:10.1016/j.gendis.2020.03.008.
34. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. *Allergy*. 2020; PG-. doi:10.1111/all.14289.
35. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. *Infection*. 2020; PG-1-8:1–8. doi:10.1007/s15010-020-01427-2.
36. Dong Y, Dong Y, Mo X, Hu Y, Qi X, Jiang F, et al. Epidemiology of COVID-19 among children in China. *Pediatrics*. 2020; PG-. doi:10.1542/peds.2020-0702.
37. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382 18 PG-1708–1720:1708–20. doi:10.1056/NEJMoa2002032.
38. He G, Sun W, Fang P, Huang J, Gamber M, Cai J, et al. The clinical feature of silent infections of novel coronavirus infection (COVID-19) in Wenzhou. *J Med Virol*. 2020; PG-. doi:10.1002/jmv.25861.
39. Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. *J Infect*. 2020; PG-. doi:10.1016/j.jinf.2020.04.001.
40. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *Bmj*. 2020;368 PG-m606:m606. doi:10.1136/bmj.m606.
41. Song W, Li J, Zou N, Guan W, Pan J, Xu W. Clinical features of pediatric patients with coronavirus disease (COVID-19). *J Clin Virol*. 2020;127 PG-104377:104377. doi:10.1016/j.jcv.2020.104377.
42. Song R, Han B, Song M, Wang L, Conlon CP, Dong T, et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. *J Infect*. 2020; PG-. doi:10.1016/j.jinf.2020.04.018.
43. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol*. 2020;55 5 PG-1169–1174:1169–74. doi:10.1002/ppul.24718.
44. Shi Y, Wang X, Liu G, Zhu Q, Wang J, Yu H, et al. A quickly, effectively screening process of novel coronavirus disease 2019 (COVID-19) in children in Shanghai, China. *Ann Transl Med*. 2020;8 5 PG-241:241. doi:10.21037/atm.2020.03.22.
45. Wu H, Zhu H, Yuan C, Yao C, Luo W, Shen X, et al. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Netw Open*. 2020;3 6 PG-e2010895:e2010895. doi:10.1001/jamanetworkopen.2020.10895.
46. Zheng F, Liao C, Fan QH, Chen HB, Zhao XG, Xie ZG, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. *Curr Med Sci*. 2020;40 2 PG-275–280:275–80. doi:10.1007/s11596-020-2172-6.
47. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science (80-)*. 2020; PG-. doi:10.1126/science.abb8001.
48. Xiong XL, Wong KK, Chi SQ, Zhou AF, Tang JQ, Zhou LS, et al. Comparative study of the clinical characteristics and epidemiological trend of 244 COVID-19 infected children with or without GI symptoms. *Gut*. 2020; PG-. doi:10.1136/gutjnl-2020-321486.

49. Hua CZ, Miao ZP, Zheng JS, Huang Q, Sun QF, Lu HP, et al. Epidemiological features and viral shedding in children with SARS-CoV-2 infection. *J Med Virol.* 2020; PG-. doi:10.1002/jmv.26180.
50. Li Y, Wang H, Wang F, Du H, Liu X, Chen P, et al. Comparison of Hospitalized Patients with pneumonia caused by COVID-19 and influenza A in children under 5 years. *Int J Infect Dis.* 2020; PG-. doi:10.1016/j.ijid.2020.06.026.
51. Yuan C, Zhu H, Yang Y, Cai X, Xiang F, Wu H, et al. Viral loads in throat and anal swabs in children infected with SARS-CoV-2. *Emerg Microbes Infect.* 2020;9 1 PG-1233–1237:1233–7. doi:10.1080/22221751.2020.1771219.
52. Du W, Yu J, Liu X, Chen H, Lin L, Li Q. Persistence of SARS-CoV-2 virus RNA in feces: A case series of children. *J Infect Public Heal.* 2020;13 7 PG-926–31:926–31. doi:10.1016/j.jiph.2020.05.025.
53. Sun D, Chen X, Li H, Lu XX, Xiao H, Zhang FR, et al. SARS-CoV-2 infection in infants under 1 year of age in Wuhan City, China. *World J Pediatr.* 2020;16 3 PG-260–266:260–6. doi:10.1007/s12519-020-00368-y.
54. Lu Y, Li Y, Deng W, Liu M, He Y, Huang L, et al. Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan. *Pediatr Infect Dis J.* 2020;39 7 PG-95–99:e95–9. doi:10.1097/inf.0000000000002729.
55. Chen Z, Tong L, Zhou Y, Hua C, Wang W, Fu J, et al. Childhood COVID-19: a multi-center retrospective study. *Clin Microbiol Infect.* 2020; PG-. doi:10.1016/j.cmi.2020.06.015.
56. Du H, Dong X, Zhang J jin, Cao Y yuan, Akdis M, Huang P qi, et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. *Allergy.* 2020; PG-. doi:10.1111/all.14452.
57. Xiong X, Chua GT, Chi S, Wah Kwan MY, Sang Wong WH, Zhou A, et al. A Comparison Between Chinese Children Infected with COVID-19 and with SARS. *J Pediatr.* 2020; PG-. doi:10.1016/j.jpeds.2020.06.041.
58. Zhao C, Xu Y, Zhang X, Zhong Y, Long L, Zhan W, et al. Public health initiatives from hospitalized patients with COVID-19, China. *J Infect Public Heal.* 2020; PG-. doi:10.1016/j.jiph.2020.06.013.
59. Gao Q, Hu Y, Dai Z, Xiao F, Wang J, Wu J. The epidemiological characteristics of 2019 novel coronavirus diseases (COVID-19) in Jingmen, Hubei, China. *Med.* 2020;99 23 PG-e20605:e20605. doi:10.1097/md.00000000000020605.
60. Ma H, Hu J, Tian J, Zhou X, Li H, Laws MT, et al. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. *BMC Med.* 2020;18 1 PG-123:123. doi:10.1186/s12916-020-01596-9.
61. Ma Y, Xu QN, Wang FL, Ma XM, Wang XY, Zhang XG, et al. Characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, China. *Microbes Infect.* 2020;22:212–7. doi:10.1016/j.micinf.2020.04.011.
62. Asfahan S, Deokar K, Dutt N, Niwas R, Jain P, Agarwal M. Extrapolation of mortality in COVID-19: Exploring the role of age, sex, co-morbidities and health-care related occupation. *Monaldi Arch Chest Dis.* 2020;90 2 PG-. doi:10.4081/monaldi.2020.1325.
63. Zhang B, Liu S, Zhang J, Xiao J, Zhu S, Dong Y, et al. Children hospitalized for coronavirus disease 2019 (COVID-19): A multicenter retrospective descriptive study. *J Infect.* 2020; PG-. doi:10.1016/j.jinf.2020.04.045.
64. Zhao W, Wang Y, Tang Y, Zhao W, Fan Y, Liu G, et al. Characteristics of Children With Reactivation of SARS-CoV-2 Infection After Hospital Discharge. *Clin Pediatr.* 2020; PG-9922820928057:9922820928057. doi:10.1177/0009922820928057.

65. Shen N, Zhu Y, Wang X, Peng J, Liu W, Wang F, et al. Characteristics and diagnosis rate of 5630 subjects receiving SARS-CoV-2 nucleic acid tests from Wuhan, China. *JCI Insight*. 2020;5 10 PG-. doi:10.1172/jci.insight.137662.
66. Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, et al. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. *PLoS Med*. 2020;17 6 PG-e1003130:e1003130. doi:10.1371/journal.pmed.1003130.
67. Liu T, Liang W, Zhong H, He J, Chen Z, He G, et al. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. *Emerg Microbes Infect*. 2020; PG-1-31:1–31. doi:10.1080/22221751.2020.1787799.
68. Lu Y, Wen H, Rong D, Zhou Z, Liu H. Clinical characteristics and radiological features of children infected with the 2019 novel coronavirus. *Clin Radiol*. 2020;75 7 PG-520–525:520–5. doi:10.1016/j.crad.2020.04.010.
69. Zhang L, Huang S. Clinical Features of 33 Cases in Children Infected With SARS-CoV-2 in Anhui Province, China-A Multi-Center Retrospective Cohort Study. *Front Public Heal*. 2020;8 PG-255:255. doi:10.3389/fpubh.2020.00255.
70. Bai K, Liu W, Liu C, Fu Y, Hu J, Qin Y, et al. *Pediatr Infect Dis J*. 2020; PG-. doi:10.1097/inf.0000000000002740.
71. Peng H, Gao P, Xu Q, Liu M, Peng J, Wang Y, et al. Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes. *J Clin Virol*. 2020;128 PG-104425:104425. doi:10.1016/j.jcv.2020.104425.
72. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020.
73. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. *Emerg Infect Dis*. 2020;26 10 PG-. doi:10.3201/eid2610.202403.
74. Posfay-Barbe KM, Wagner N, Gauthey M, Moussaoui D, Loevy N, Diana A, et al. COVID-19 in Children and the Dynamics of Infection in Families. *Pediatrics*. 2020; PG-. doi:10.1542/peds.2020-1576.
75. Schwierzeck V, König JC, Kühn J, Mellmann A, Correa-Martínez CL, Omran H, et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. *Clin Infect Dis*. 2020; PG-. doi:10.1093/cid/ciaa491.
76. Melgosa M, Madrid A, Álvarez O, Lumbreras J, Nieto F, Parada E, et al. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. *Pediatr Nephrol*. 2020;35 8 PG-1521–1524:1521–4. doi:10.1007/s00467-020-04597-1.
77. de Ceano-Vivas M, Martín-Espín I, Del Rosal T, Bueno-Barriocanal M, Plata-Gallardo M, Ruiz-Domínguez JA, et al. SARS-CoV-2 infection in ambulatory and hospitalised Spanish children. *Arch Dis Child*. 2020; PG-. doi:10.1136/archdischild-2020-319366.
78. González Cortés R, García-Salido A, Roca Pascual D, Slöcker Barrio M, de Carlos Vicente JC. A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units. *Intensive Care Med*. 2020; PG-1-3:1–3. doi:10.1007/s00134-020-06146-8.
79. García-Salido A, Leoz-Gordillo I, Martínez de Azagra-Garde A, Nieto-Moro M, Iglesias-Bouzas MI, García-Teresa MÁ, et al. Children in Critical Care Due to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Experience in a Spanish Hospital. *Pediatr Crit Care Med*. 2020; PG-.

doi:10.1097/pcc.0000000000002475.

80. Danis K, Epaulard O, Bénét T, Gaymard A, Campoy S, Bothelo-Nevers E, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. *Clin Infect Dis*. 2020; PG-. doi:10.1093/cid/ciaa424.
81. Dimeglio C, Mansuy JM, Charpentier S, Claudet I, Izopet J. Children are protected against SARS-CoV-2 infection. *J Clin Virol*. 2020;128 PG-104451:104451. doi:10.1016/j.jcv.2020.104451.
82. Oualha M, Bendavid M, Berteloot L, Corsia A, Lesage F, Vedrenne M, et al. Severe and fatal forms of COVID-19 in children. *Arch Pediatr*. 2020;27 5 PG-235–238:235–8. doi:10.1016/j.arcped.2020.05.010.
83. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. *Lancet Infect Dis*. 2020; PG-. doi:10.1016/s1473-3099(20)30371-6.
84. Harman K, Verma A, Cook J, Radia T, Zuckerman M, Deep A, et al. Ethnicity and COVID-19 in children with comorbidities. *Lancet Child Adolesc Heal*. 2020;4 7 PG-24–25:e24–5. doi:10.1016/s2352-4642(20)30167-x.
85. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*. 2020; PG-. doi:10.1038/s41586-020-2488-1.
86. Parri N, Lenge M, Buonsenso D. Children with Covid-19 in Pediatric Emergency Departments in Italy. *N Engl J Med*. 2020; PG-. doi:10.1056/NEJMc2007617.
87. Dodi I, Castellone E, Pappalardo M, Rubini M, Veronese P, Ruberto C, et al. SARS-CoV-2 infection in children in Parma. *Acta Biomed*. 2020;91 2 PG-214–215:214–5. doi:10.23750/abm.v91i2.9563.
88. Garazzino S, Montagnani C, Donà D, Meini A, Felici E, Vergine G, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. *Euro Surveill*. 2020;25 18 PG-. doi:10.2807/1560-7917.Es.2020.25.18.2000600.
89. De Ioris MA, Scarselli A, Ciofi Degli Atti ML, Ravà L, Smarrazzo A, Concato C, et al. Dynamic viral SARS-CoV-2 RNA shedding in in children: preliminary data and clinical consideration of Italian regional center. *J Pediatr Infect Dis Soc*. 2020; PG-. doi:10.1093/jpids/piaa065.
90. Moratto D, Giacomelli M, Chiarini M, Savarè L, Sacconi B, Motta M, et al. Immune response in children with COVID-19 is characterized by lower levels of T cell activation than infected adults. *Eur J Immunol*. 2020; PG-. doi:10.1002/eji.202048724.
91. Brambilla I, Castagnoli R, Caimmi S, Ciprandi G, Luigi Marseglia G. COVID-19 in the Pediatric Population Admitted to a Tertiary Referral Hospital in Northern Italy: Preliminary Clinical Data. *Pediatr Infect Dis J*. 2020;39 7 PG-e160:e160. doi:10.1097/inf.0000000000002730.
92. Valente P, Iarossi G, Federici M, Petroni S, Palma P, Cotugno N, et al. Ocular manifestations and viral shedding in tears of pediatric patients with coronavirus disease 2019: a preliminary report. *J aapos*. 2020; PG-. doi:10.1016/j.jaapos.2020.05.002.
93. Parri N, Magistà AM, Marchetti F, Cantoni B, Arrighini A, Romanengo M, et al. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks. *Eur J Pediatr*. 2020; PG-1-9:1–9. doi:10.1007/s00431-020-03683-8.
94. Talarico V, Nicoletti A, Sabetta L, Minchella P, Raiola G. Preliminary epidemiological analysis on children and adolescents with novel coronavirus disease (2019-nCoV) in a central area of Calabria region. *Acta*

Biomed. 2020;91 2 PG-232–233:232–3. doi:10.23750/abm.v91i2.9550.

95. Gujski M, Raciborski F, Jankowski M, Nowicka PM, Rakocy K, Pinkas J. Epidemiological Analysis of the First 1389 Cases of COVID-19 in Poland: A Preliminary Report. *Med Sci Monit.* 2020;26 PG-e924702:e924702. doi:10.12659/msm.924702.

96. Hildenwall H, Luthander J, Rhedin S, Hertting O, Olsson-Åkefeldt S, Melén E, et al. Paediatric COVID-19 admissions in a region with open schools during the two first months of the pandemic. *Acta Paediatr.* 2020; PG-. doi:10.1111/apa.15432.

97. US Centers for Disease Control and Prevention. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69 12 PG-343–346:343–6. doi:10.15585/mmwr.mm6912e2.

98. Rha B, Lively JY, Englund JA, Staat MA, Weinberg GA, Selvarangan R, et al. SARS-CoV-2 Infections in Children - Multi-Center Surveillance, United States, January-March 2020. *J Pediatr Infect Dis Soc.* 2020; PG-. doi:10.1093/jpids/piaa075.

99. Ranabothu S, Onteddu S, Nalleballe K, Dandu V, Veerapaneni K, Veerapandiyan A. Spectrum of COVID-19 in Children. *Acta Paediatr.* 2020; PG-. doi:10.1111/apa.15412.

100. Mithal LB, Machut KZ, Muller WJ, Kociolek LK. SARS-CoV-2 Infection in Infants Less than 90 Days Old. *J Pediatr.* 2020; PG-.

101. Otto WR, Geoghegan S, Posch LC, Bell LM, Coffin SE, Sammons JS, et al. The Epidemiology of SARS-CoV-2 in a Pediatric Healthcare Network in the United States. *J Pediatr Infect Dis Soc.* 2020; PG-. doi:10.1093/jpids/piaa074.

102. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. *JAMA Pediatr.* 2020; PG-e202430:e202430. doi:10.1001/jamapediatrics.2020.2430.

103. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and Other Clinical Characteristics of COVID-19 in Children. *Pediatrics.* 2020;146 1 PG-. doi:10.1542/peds.2020-0961.

104. Mannheim J, Gretsche S, Layden JE, Fricchione MJ. Characteristics of Hospitalized Pediatric COVID-19 Cases - Chicago, Illinois, March - April 2020. *J Pediatr Infect Dis Soc.* 2020; PG-. doi:10.1093/jpids/piaa070.

105. Foster CE, Moulton EA, Munoz FM, Hulten KG, Versalovic J, Dunn J, et al. Coronavirus Disease 2019 in Children Cared for at Texas Children's Hospital: Initial Clinical Characteristics and Outcomes. *J Pediatr Infect Dis Soc.* 2020; PG-. doi:10.1093/jpids/piaa072.

106. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatr.* 2020; PG-. doi:10.1001/jamapediatrics.2020.1948.

107. Zachariah P, Halabi KC, Johnson CL, Whitter S, Sepulveda J, Green DA. Symptomatic Infants have Higher Nasopharyngeal SARS-CoV-2 Viral Loads but Less Severe Disease than Older Children. *Clin Infect Dis.* 2020; PG-. doi:10.1093/cid/ciaa608.

108. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region. *J Pediatr.* 2020; PG-. doi:10.1016/j.jpeds.2020.05.007.

109. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med.* 2020;26 4 PG-502–505:502–5.

doi:10.1038/s41591-020-0817-4.

110. Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Euro Surveill.* 2020;25 12 PG-. doi:10.2807/1560-7917.Es.2020.25.12.2000256.

111. Korkmaz MF, Türe E, Dorum BA, Kılıç ZB. The Epidemiological and Clinical Characteristics of 81 Children with COVID-19 in a Pandemic Hospital in Turkey: an Observational Cohort Study. *J Korean Med Sci.* 2020;35 25 PG-e236:e236. doi:10.3346/jkms.2020.35.e236.

112. Han MS, Seong MW, Kim N, Shin S, Cho SI, Park H, et al. Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul. *Emerg Infect Dis.* 2020;26 10 PG-. doi:10.3201/eid2610.202449.

113. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.* 2020;63 5 PG-706–711:706–11. doi:10.1007/s11427-020-1661-4.

114. Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. *Euro Surveill.* 2020;25 21 PG-. doi:10.2807/1560-7917.Es.2020.25.21.2000903.

115. Park YJ, Choe YJ, Park O, Park SY, Kim Y-M, Kim J, et al. Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. *Emerg Infect Dis J.* 2020;26 10 PG-. doi:10.3201/eid2610.201315.

116. Ibrahim LF, Tosif S, McNab S, Hall S, Lee HJ, Lewena S, et al. SARS-CoV-2 testing and outcomes in the first 30 days after the first case of COVID-19 at an Australian children's hospital. *Emerg Med Australas.* 2020; PG-. doi:10.1111/1742-6723.13550.

117. Somekh E, Gleyzer A, Heller E, Lopian M, Kashani-Ligumski L, Czeiger S, et al. The Role of Children in the Dynamics of Intra Family Coronavirus 2019 Spread in Densely Populated Area. *Pediatr Infect Dis J.* 2020; PG-. doi:10.1097/inf.0000000000002783.

118. Han MS, Choi EH, Chang SH, Jin B Lo, Lee EJ, Kim BN, et al. Clinical Characteristics and Viral RNA Detection in Children with Coronavirus Disease 2019 in the Republic of Korea. *JAMA Pediatr.* 2020.

119. Alvarado GR, Pierson BC, Teemer ES, Gama HJ, Cole RD, Jang SS. Symptom Characterization and Outcomes of Sailors in Isolation After a COVID-19 Outbreak on a US Aircraft Carrier. *JAMA Netw open.* 2020;3:e2020981. doi:10.1001/jamanetworkopen.2020.20981.

120. He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. *J Med Virol.* 2020;;jmv.26326. doi:10.1002/jmv.26326.

121. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. *Clin Infect Dis.* 2020. doi:10.1093/cid/ciaa576.

122. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *Jama.* 2020; PG-. doi:10.1001/jama.2020.10369.

123. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med.* 2020; PG-. doi:10.1056/NEJMoa2021680.

124. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. 2020;395:10239. doi:10.1016/S0140-6736(20)31103-x.
125. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatrica, International Journal of Paediatrics*. 2020.
126. Moraga P, Ketcheson DI, Ombao HC, Duarte CM. Assessing the age- and gender-dependence of the severity and case fatality rates of COVID-19 disease in Spain. *Wellcome Open Res*. 2020.
127. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries. *medRxiv*. 2020.
128. Corman VM, Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, et al. An analysis of SARS-CoV-2 viral load by patient age. *medRxiv*. 2020;:2020.06.08.20125484. doi:10.1101/2020.06.08.20125484.
129. Baggio S, L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, et al. SARS-CoV-2 viral load in the upper respiratory tract of children and adults with early acute COVID-19. *Clin Infect Dis*. 2020. doi:10.1093/cid/ciaa1157.
130. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for transmission of covid-19 prior to symptom onset. *Elife*. 2020;9:1–34. doi:10.7554/eLife.57149.
131. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020;382:2081–90. doi:10.1056/NEJMoa2008457.
132. Furuse Y, Sando E, Tsuchiya N, Miyahara R, Yasuda I, K.Ko Y, et al. Clusters of coronavirus disease in communities, Japan, January–April 2020. *Emerg Infect Dis*. 2020;26:2176–9. doi:10.3201/eid2609.202272.
133. Kim J, Choe YJ, Lee J, Park YJ, Park O, Han MS, et al. Role of children in household transmission of COVID-19. *Arch Dis Child*. 2020;0:1–3. doi:10.1136/archdischild-2020-319910.
134. Macartney K, Quinn HE, Pillsbury AJ, Koirala A, Deng L, Winkler N, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. *Lancet Child Adolesc Heal*. 2020;0. doi:10.1016/S2352-4642(20)30251-0.
135. Laxminarayan R, Wahl B, Reddy Dudala S, Gopal K, Mohan C, Neelima S, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* (80-). 2020. <https://science.sciencemag.org/content/early/2020/09/29/science.abd7672>.
136. Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M, Cardash T, et al. A large COVID-19 outbreak in a high school 10 days after schools' reopening, Israel, May 2020. *Eurosurveillance*. 2020;25:2001352. doi:10.2807/1560-7917.ES.2020.25.29.2001352.
137. Link G. A risky game with health and lives as schools reopen throughout Germany - World Socialist Web Site. <https://www.wsws.org/en/articles/2020/08/17/germ-a17.html>. Accessed 30 Sep 2020.
138. CBC News. 41 schools report coronavirus in Berlin | CBC News. <https://www.cbc.ca/news/health/virus-schools-berlin-1.5694994>. Accessed 30 Sep 2020.
139. Szablewski CM, Chang KT, Brown MM, Chu VT, Yousaf AR, Anyalechi N, et al. Morbidity and Mortality Weekly Report SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp-Georgia, June 2020. doi:10.15585/mmwr.
140. Ehrhardt J, Ekinci A, Krehl H, Meincke M, Finci I, Klein J, et al. Transmission of SARS-CoV-2 in children aged 0 to 19 years in childcare facilities and schools after their reopening in May 2020, Baden-

Württemberg, Germany. Eurosurveillance. 2020;25:2001587. doi:10.2807/1560-7917.ES.2020.25.36.2001587.

141. Fong M, Cowling B, Leung G, Wu P. Letter to the editor: COVID-19 cases among school-aged children and school-based measures in Hong Kong, July 2020. Eurosurveillance. 2020;25:2001671.

142. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults. JAMA Pediatr. 2020. doi:10.1001/jamapediatrics.2020.4573.

143. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.4130.

144. US Centers for Disease Control and Prevention. CDC COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fcommercial-labs-interactive-serology-dashboard.html#serology-surveillance. Accessed 30 Sep 2020.

145. Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Regional Difference in Seroprevalence of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing. medRxiv. 2020;:2020.06.03.20121020. doi:10.1101/2020.06.03.20121020.

146. Figar S, Pagotto V, Luna L, Salto J, Wagner M, 4 M, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. Cold Spring Harbor Laboratory Press; 2020. doi:10.1101/2020.07.14.20153858.

147. Sant Joan de Deu Barcelona Children's Hospital. First conclusions of the COVID-19 investigation in children. 2020. <https://www.sjdhospitalbarcelona.org/en/children-have-similar-prevalence-covid-19-antibodies-adults-more-99-have-mild-symptoms>. Accessed 30 Sep 2020.

148. Flamand C, Enfissi A, Bailly S, Sarmiento CA, Beillard E, Gaillet M, et al. Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. doi:10.1101/2020.09.27.20202465.

149. Dingens AS, Crawford KH, Adler A, Steele SL, Lacombe K, Eguia R, et al. Seroprevalence of SARS-CoV-2 among children visiting a hospital during the initial Seattle outbreak. medRxiv Prepr Serv Heal Sci. 2020. doi:10.1101/2020.05.26.20114124.

150. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. The New England journal of medicine. 2020;383:1085–7. doi:10.1056/NEJMc2025179.

151. Burgess S, Ponsford MJ, Gill D. Are we underestimating seroprevalence of SARS-CoV-2? The BMJ. 2020;370. doi:10.1136/bmj.m3364.